Form 4: Tarsus Pharmaceuticals Executive Dianne C. Whitfield Reports Stock Option and RSU Grant

Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, reports the acquisition of stock options and restricted stock units (RSUs) on March 7, 2024.

Summary

• Dianne C. Whitfield, the Chief Human Resources Officer of Tarsus Pharmaceuticals, filed a Form 4 with the SEC.
• The filing reports the grant of stock options and restricted stock units (RSUs) to Whitfield on March 7, 2024.
• Whitfield acquired options to purchase 42,500 shares of common stock at an exercise price of $35.50.
• These options vest over four years, with 25% vesting on March 7, 2025, and the remainder vesting monthly over the subsequent three years, contingent upon continued service.
• Whitfield also acquired 28,702 RSUs, each representing a contingent right to receive one share of Tarsus Pharmaceuticals common stock.
• These RSUs vest in four equal installments of 25% on March 15th of each of 2025, 2026, 2027, and 2028, subject to continuous service.
• Following these transactions, Whitfield directly owns 42,500 stock options and 28,702 RSUs.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of executive compensation, which is generally neutral. The vesting schedules are positive as they incentivize long-term commitment.

Positives

• The grant of stock options and RSUs aligns Whitfield's interests with those of the shareholders, incentivizing her to contribute to the company's long-term success.
• The vesting schedules encourage continued service and commitment from Whitfield.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Stock option and RSU grants are common forms of executive compensation in the pharmaceutical industry.
• Vesting schedules are typically structured to incentivize long-term performance and retention, similar to practices at companies like Allergan (now AbbVie) and Bausch Health.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's performance.
• Employees may see the grants as a positive indicator of the company's commitment to its leadership team.

Key Dates